Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).

Published in:

Journal of Patient-Reported Outcomes, 2018, v. 2, n. 1, p. N.PAG, doi. 10.1186/s41687-018-0054-5

By:

• Unger, Joseph M.;
• Griffin, Katherine;
• Donaldson, Gary W.;
• Baranowski, Karen M.;
• Good, Margorie J.;
• Reburiano, Eunicia;
• Hussain, Maha;
• Monk, Paul J.;
• Van Veldhuizen, Peter J.;
• Carducci, Michael A.;
• Higano, Celestia S.;
• Lara, Primo N.;
• Tangen, Catherine M.;
• Quinn, David I.;
• Wade, James L.;
• III;
• Vogelzang, Nicholas J.;
• Thompson, Ian M.;
• Jr;
• Moinpour, Carol M.

Publication type:

Article